Compare DexCom, Inc. (DXCM) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Alliant Energy Corporation — how do they compare? DexCom, Inc. trades at $84 (market cap $31.86B), while Alliant Energy Corporation trades at $65.7 (market cap $16.99B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Alliant Energy Corporation pays a 3.27% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Alliant Energy Corporation for 64 Days on average.
| DXCM | LNT | |
|---|---|---|
Market Cap | $31.86B | $16.99B |
Volume | 3,607,070 | 2,488,387 |
Sector | Health | Utilities |
52-Week High | $92.34 | $78.03 |
52-Week Low | $54.84 | $63.21 |
Typical Hold Time | 62 Days | 64 Days |
Enterprise Value | $31.32B | $29.08B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
LNT trades at $65.21, down 0.43% on the day, with a bullish technical signal despite mixed indicators. The company reported Q2 2026 EPS of $0.65, beating estimates, and maintains a strong profitability profile with an 18.45% net income margin. Recent news highlights institutional buying and a $1.4 billion partnership expansion, though the stock recently touched a 52-week low.
The outlook is supported by a $13.4 billion capital investment plan and data center demand growth, offering potential upside to the $77 consensus price target. Risks include rising debt levels and cost pressures, but analyst sentiment remains positive with no sell ratings. The stock presents a defensive income opportunity with a growing dividend.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
